en.Wedoany.com Reported - An observational study led by Elizabeth McDonald, a professor of radiology at the Perelman School of Medicine at the University of Pennsylvania, found that individuals taking GLP-1 drugs had a 35% lower rate of breast cancer diagnosis. The study included over 110,000 cases, with data sourced from a program managed by the American College of Radiology (ACR), and was presented at the American Society of Clinical Oncology annual meeting.

There is substantial data supporting the therapeutic effects of GLP-1 drugs in cardiovascular disease, addiction, kidney and liver diseases, but little is known about how these drugs affect tumor-related disease progression. This new finding suggests a potential real link between GLP-1 use and reduced cancer risk, though it does not prove causation. Etta D. Pisano, ACR's Chief Research Officer, stated that the results warrant further investigation. She noted that breast cancer deaths have declined by over 40% in the past 40 years due to screening and improved therapies, and a large prospective study could help determine whether GLP-1 drugs can help more women avoid the disease. ACR officials are now calling for additional funding for broader research to explore the potential impact of these drugs on cancer incidence and prevention.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com